MedTrace Logo

Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia

NCT00005880 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-07-24

No results posted yet for this study

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of budesonide may be an effective way to prevent bronchial dysplasia.

PURPOSE: Randomized double-blinded phase II trial to determine the effectiveness of budesonide in treating former or current smokers who have bronchial dysplasia.

Conditions

Interventions

DRUG

budesonide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Stephen Lam, MD · British Columbia Cancer Agency

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005880 on ClinicalTrials.gov